

Amendments to the Claims

1. (Currently amended) A modified botulinum neurotoxin type A, wherein the modification ~~comprises~~ is one or more additional amino acid sequences comprising SEQ ID NO: 27 within the N-terminal 30 amino acids of a wild-type botulinum toxin type A light chain from a ~~botulinum toxin type A~~,

wherein the additional amino acid sequence comprising SEQ ID NO: 27 increases biological half-life of the modified botulinum neurotoxin type A relative to an identical botulinum neurotoxin type A without the additional amino acid sequence comprising SEQ ID NO: 27.

2-46. (Canceled)

47. (Currently amended) The modified botulinum neurotoxin type A of Claim 1, further comprising a modification of adding one or more additional leucine-based motifs of SEQ ID NO: 18 within the C-terminal 50 amino acids of the wild-type botulinum toxin type A light chain,

wherein the additional leucine-based motif of SEQ ID NO: 18 increases biological half-life of the modified botulinum neurotoxin type A relative to an identical botulinum neurotoxin type A without the additional leucine-based motif.

48. (Previously presented) The modified botulinum neurotoxin type A of Claim 47, wherein the additional leucine-based motif is SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 13.

49-60. (Canceled)